Cengild Medical Bhd (XKLS:0243) ROCE %: 5.71% (As of Mar. 2026)


XKLS:0243 Cengild Medical Bhd XKLS:0243
67 GF Score
Price RM0.20
GF Value RM0.29
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Cengild Medical Bhd ROCE %?

Cengild Medical Bhd XKLS:0243 67 ROCE % is 5.71% as of Mar. 2026. GuruFocus rates XKLS:0243 with a GF Score™ of 67/100 and a GF Value™ of RM0.29 (Significantly Undervalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cengild Medical Bhd's annualized ROCE % for the quarter that ended in Mar. 2026 was 5.71%.

Cengild Medical Bhd  (XKLS:0243) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cengild Medical Bhd ROCE % Related Terms

Cengild Medical Bhd ROCE % Historical Data

* Premium members only.

The historical data trend for Cengild Medical Bhd's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cengild Medical Bhd ROCE % Chart

Cengild Medical Bhd Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial 42.59 18.14 15.87 14.57 13.23

Cengild Medical Bhd Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.74 8.94 9.36 7.73 5.71
XKLS:0243
67GF Score
Cengild Medical Bhd XKLS:0243
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cengild Medical Bhd ROCE % Calculation

Cengild Medical Bhd's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=18.393/( ( (132.443 - 14.765) + (180.489 - 20.054) )/ 2 )
=18.393/( (117.678+160.435)/ 2 )
=18.393/139.0565
=13.23 %

Cengild Medical Bhd's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=11.396/( ( (218.069 - 19.879) + (217.91 - 17.148) )/ 2 )
=11.396/( ( 198.19 + 200.762 )/ 2 )
=11.396/199.476
=5.71 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 5.71% mean?
Cengild Medical Bhd (XKLS:0243) has a ROCE % of 5.71% as of Mar. 2026.
Is Cengild Medical Bhd's ROCE % too high?
Cengild Medical Bhd's current ROCE % is 5.71%. The Healthcare Providers & Services industry median ROCE % is 6.41. Cengild Medical Bhd's value of 5.71% is 10.9% below this industry median. Overall, Cengild Medical Bhd has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cengild Medical Bhd's ROCE % compare to HCA and THC?
Cengild Medical Bhd's ROCE % of 5.71% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. Cengild Medical Bhd's value of 5.71% is 10.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 646 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cengild Medical Bhd's current ROCE % of 5.71% is 10.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cengild Medical Bhd's current ROCE % is 5.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cengild Medical Bhd stock overvalued right now?
Based on GuruFocus' analysis, Cengild Medical Bhd (XKLS:0243) is currently considered Significantly Undervalued. The stock's GF Value™ is RM0.29, compared to a current price of RM0.20 — trading 31% below its estimated fair value. The current ROCE % is 5.71% and 10.9% below the Healthcare Providers & Services industry median of 6.41. Cengild Medical Bhd's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Cengild Medical Bhd (XKLS:0243), the current ROCE % is 5.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cengild Medical Bhd (XKLS:0243) Overvalued in 2026?

Based on GuruFocus' analysis, Cengild Medical Bhd stock appears to be undervalued. The current stock price of RM0.20 is trading 31% below its estimated GF Value™ of RM0.29. GuruFocus considers Cengild Medical Bhd to be Significantly Undervalued.

Key valuation signals for XKLS:0243:

  • ROCE %: 5.71%
  • GF Value™: RM0.29 vs. price of RM0.20 (31% below fair value)
  • GF Score™: 67/100 with 5 warning signs
  • Industry Position: 10.9% below the Healthcare Providers & Services median

No single metric tells the full story. See the XKLS:0243 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cengild Medical Bhd Business Description

Address No.7, Jalan Kerinchi, Unit 2-3 & 2-4, Level 2, Nexus, Bangsar South, Kuala Lumpur, MYS, 59200
Cengild Medical Bhd is a healthcare service provider operating a medical centre specializing in the diagnosis and treatment of gastrointestinal-related diseases, oncology, gynecology services., liver diseases, and obesity. The company operates in Malaysia and has two reportable segments, Consultant Services and Medical Management Services. A substantial portion of the overall revenue is generated from its Medical Management Services segment.
67GF Score

Get the complete analysis for XKLS:0243

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM0.20
Price
RM0.29
GF Value